Cost per arrived international patient, by market
Cost per arrived international patient is everything spent creating and converting demand from abroad, divided by patients who actually travelled and registered. Include media, localisation, country pages, events, partner commissions and desk time before arrival; keep service costs separate. Record first contact and arrival route on every case, report blended and split views, allocate shared spend by a stated rule, and read it by cohort.
Ask a hospital what an international patient costs to acquire and you usually get one of two answers. Either a cost per lead, which counts messages from people who may never leave their own city, or a commission rate, which counts only the cases a partner brought and ignores everything the hospital spent to be worth recommending. Cost per arrived international patient is the number that sits between them, and it is the only acquisition cost for medical value travel that I would put in a board pack without a paragraph of apology.
The definition is plain. Take everything you spent to create and handle international demand over a period. Divide it by the number of patients from outside the country who actually arrived and were registered. What makes it hard is not the arithmetic. It is agreeing what belongs in the numerator, and deciding what to do with a case that reached you through someone else.
This is the international version of a method I have written about for domestic demand in how to calculate cost per honoured appointment. The logic carries over. The unit does not, and neither does the cost side, because an international funnel spends money on things a domestic funnel never touches.
What cost per arrived international patient actually measures
It measures the price of a completed journey. Not the price of attention, not the price of a conversation, and not the fee attached to one referral route. A patient who boarded a flight, landed, and presented at your registration desk has passed every test your process can set: the reply was fast enough, the opinion was credible, the estimate held, the paperwork was survivable and the family trusted you more than the alternatives they were shown.
That makes the number blunt and honest at the same time. It will be higher than any cost per lead you have ever reported, and that alone causes arguments in the first month. It is also the only acquisition figure that reconciles with something outside marketing, because arrivals are recorded at registration by people with no stake in the campaign.
The counting discipline underneath it matters as much as the cost work. If your arrival count is soft, the whole calculation is decorative. I have set out how I define and count the denominator in measuring international demand honestly, and I would fix that before touching a single invoice.
Why arrival, not enquiry, is the unit
An international enquiry is cheap to create and easy to inflate. Run a broad campaign across a region, accept every message as a lead, and the cost per enquiry will look excellent while the desk drowns in cases that were never going to travel. Nothing in that number tells you whether the demand was real.
Arrival is expensive to fake. Between the message and the arrival sit a medical opinion, an estimate, money moved across a border, documents, leave from work, someone to accompany the patient, and a family conversation you will never hear. Each of those can end the case. Measuring against arrival puts the cost of all that friction where it belongs: in your acquisition number, visible, rather than hidden in a conversion rate nobody owns.
There is a practical reason too. The video consultation is not the finish line. A hospital can hold a great many online consultations with patients abroad and treat none of them, and a metric anchored on consultations will reward exactly that. The travel is the commitment. Count it.
What belongs in the cost
The numerator should contain everything spent to create, win and convert international demand, and nothing spent to serve a patient who has already decided.
In, without argument: paid media aimed at audiences outside India, agency and production cost for that work, translation and localisation of pages and video, the cost of building and maintaining country pages, participation in medical events abroad including travel and stand cost, representative or liaison arrangements in a market, partner commissions paid on arrived cases, and the loaded cost of the international desk time spent on enquiry handling and follow up before arrival.
Out, in my view: interpreters during the stay, airport pickup, attendant accommodation help, food arrangements and the rest of the in-house experience. Those are service costs. They powerfully affect whether the next patient comes, but folding them into acquisition makes the number impossible to compare across periods and hides a real management question about what hospitality actually costs you.
One line sits awkwardly between the two and deserves a decision rather than a habit: the pre travel opinion. Many hospitals give a written second opinion or a video consultation free, as part of winning the case. If it is free to the family, its cost is acquisition, and it should be counted with the consultant time it actually consumes rather than treated as goodwill. If it is charged, it is revenue and a different conversation. What you should not do is pretend it is costless because no invoice was raised.
The genuinely contested items are brand spend that reaches many markets at once and desk salaries split between selling and serving. Do not solve these with a debate. Solve them with a written allocation rule, apply it every month, and disclose it on the same page as the number. A rule that is slightly crude but stable is worth more than a precise rule that changes whenever the answer is unflattering. If you are rebuilding the spend lines anyway, the hospital marketing budget calculator on this site is a reasonable place to lay them out.
How to attribute a facilitator introduced case
This is where most international cost models fall apart, and the failure is usually a failure of honesty rather than of method.
The simple case is clean. A partner introduces a patient you had never heard of, the case arrives, a commission becomes payable on arrival. That commission is a variable acquisition cost for that case, and it belongs in the numerator in the period the patient arrived, not the period the invoice was settled.
The awkward case is the common one. A family found your country page, watched a doctor’s video, messaged your desk, then asked someone in their own city to handle the trip. The case now reaches you a second time through a partner who claims it. Your marketing spend created the preference. The partner did the last mile. Both are true, and a model that assigns the whole cost to either one is wrong.
The rule I use is to record two things on every case: the first identified contact with the hospital, and the route by which the patient actually arrived. Report a blended cost per arrived international patient for the whole market, and then a split view for direct and partner routes that shows what each carries. Do not let the blended number become the only view, because it lets a partner route look cheap while it quietly consumes the brand work that made the introduction possible. The underlying choice of routes is a strategy question in its own right, which I have taken up in facilitator, direct or hybrid.
One more discipline. Commission structures differ by partner and by case type, so never average them into a single rate for reporting. Keep the actual amounts attached to the actual cases. An average commission rate is a number that hides both your best and your worst deals.
Doing it by market
A single international acquisition cost for the whole hospital is almost useless. The work sits in reading it by market, and the obstacle is that most spend does not arrive neatly labelled by country.
Some of it does. Geo targeted media, a country page, a language specific campaign, an event in a particular city, a partner operating in one market. Attach those directly. The rest is shared, and shared spend needs a proxy that does not flatter anyone: enquiry share, language share, or desk hours logged by market, chosen once and then left alone. Write down the proxy. Every argument you will have about this number in the next year will actually be an argument about the proxy.
Where the data is thin, lean on the wider demand signal rather than inventing precision. The search, language and route evidence I describe in reading international demand from data, not anecdotes will often tell you whether a market is growing long before your own arrival counts can. A market that produced a handful of arrivals will produce a cost figure that swings wildly, and the right response is to report it as indicative and look at a longer window, not to present it with a confident face.
Currency, timing and the lag
Two mechanical problems distort this number, and both are easy to fix once named.
The first is currency. Media bought abroad, event fees and some partner payments move with the exchange rate, so a market can appear to get more expensive in a month when nothing about the market changed. Book costs in your reporting currency at a consistent rate and keep the note visible, so the conversation stays about demand rather than about treasury.
The second is lag, and it is larger than anyone expects. An international decision takes weeks or months, and the length of it varies by market because documents and travel do. Dividing this month’s cost by this month’s arrivals compares two unrelated populations. Use cohorts: take the enquiries or the spend of a period, follow that group forward, and report the cost as it matures. Say clearly which cohorts are still open. A provisional number honestly labelled is more useful than a final number that is quietly wrong.
What this number will not tell you
It will not tell you which market is best. Cost per arrived international patient sits on one side of a ledger, and the other side is what an arrived case is worth: the specialty mix, the length of stay, whether the patient pays directly or through a sponsor, whether they return for follow up and whether their family follows in the next year. A market with a higher acquisition cost and a far higher case value is not a problem to be fixed.
It will also not settle the question of whose funnel is performing better. Conversion behaviour differs between markets for structural reasons that have nothing to do with the quality of your desk, and I have taken that apart separately in why one market’s conversion rate cannot be compared with another’s. Use this number to see whether a market is getting cheaper or dearer against its own past. That is the comparison it supports.
Nor does it capture what an arrived patient brings with them. Families travel in groups, attendants need care of their own, and a satisfied case often produces the next two through a conversation in a waiting room at home that you will never see. None of that appears in the denominator, which is another reason to treat a rising acquisition cost in a market as a question rather than a verdict.
And it will not replace judgement about which markets to build in. Some markets are worth entering at a poor acquisition cost for a few years because the referral relationships compound. The number tells you what you are paying. It does not tell you what you are buying.
Where to start on Monday
Do the denominator first. Until arrivals are counted reliably with a residence flag at registration, every cost figure you produce will be argued away, and rightly.
Then assemble one quarter of cost the slow way, by hand, from the actual ledger rather than the marketing plan. Expect to find spend nobody remembered: an event, a representative arrangement, production for a language version, commissions sitting in a different cost centre. That first reconstruction is where most of the learning happens, and it is also where you will discover which invoices carry enough description to be allocated at all.
Write the allocation rules on one page. Publish the blended number and the split by route. Then hold it stable for a full year, resisting every request to redefine it mid-year, because the value of this metric is almost entirely in the trend. The first print will be uncomfortable. Show it to the leadership team before it reaches a review, explain what is in it, and let the second and third prints do the arguing for you.
Questions people ask
It is the total cost of creating, winning and converting demand from patients living outside the country over a period, divided by the number of those patients who actually travelled and registered at the hospital. It counts arrivals rather than enquiries or online consultations, so it reflects every point where a case can fall away, including documents, money movement and the family decision behind the trip.
Because international enquiries are cheap to generate and easy to inflate with broad campaigns across a region. A low cost per enquiry can sit alongside a desk full of cases that were never going to travel. Arrival is hard to fake, so anchoring on it puts the cost of every point of friction into the acquisition number instead of hiding it inside a conversion rate that nobody owns.
Paid media aimed outside the country, agency and production for that work, translation and localisation, country page build and upkeep, events abroad including travel, representative arrangements in a market, partner commissions on arrived cases, and the loaded cost of desk time spent before arrival. Service costs during the stay, such as interpreters, pickup and attendant help, are managed separately so the acquisition number stays comparable across periods.
Record two facts on every case: the first identified contact with the hospital and the route by which the patient actually arrived. Commission counts as a variable acquisition cost in the period of arrival. Report a blended figure for the market and a split view for direct and partner routes, so a partner route is not shown as cheap while quietly consuming the brand work that made the introduction credible.
Treat it as a shared outcome rather than forcing a single owner. Your spend created the preference and the partner completed the trip, and both facts should be visible on the case. Keeping first contact and arrival route as separate fields lets you see how often this happens in each market, which is itself a useful signal about how much of your own demand is being intercepted late in the journey.
The denominator comes from registration records rather than from a marketing tool, so it can be reconciled with the hospital information system. The numerator should be built from the ledger, not from the marketing plan, with a written allocation rule for shared costs. Ask to see that rule, ask whether it changed during the year, and ask which cohorts are still open when a figure is presented.
Attach whatever can be attached directly: geo targeted media, country pages, language campaigns, events and market specific partners. Split the rest by a stated proxy such as enquiry share, language share or logged desk hours. Choose the proxy once, write it down and leave it alone. Almost every dispute about this metric turns out to be a dispute about the proxy rather than about the spend itself.
Yes, and visibly. Media bought abroad, event fees and some partner payments move with the exchange rate, so a market can look more expensive in a month when nothing about demand changed. Book costs in your reporting currency at a consistent rate and keep a note on the same page as the number, so the discussion stays about patients rather than about treasury decisions nobody in the room controls.
Because an international decision runs far longer than a domestic one and the length differs by market, since documents and travel differ. Dividing this period’s cost by this period’s arrivals compares two unrelated groups of families. Cohort reporting fixes it: follow the spend or the enquiries of a period forward and label which cohorts are still open when you present the result.
Use it to compare a market against its own past, not against another market. Acquisition cost sits on one side of the ledger and case value sits on the other, and the mix of specialties, payers, stay lengths and repeat behaviour differs sharply. A market that costs more to win and delivers far more value per case is not a problem. Ranking markets on cost alone leads to bad exits.
Monthly for direction and quarterly for decisions. Month to month movement in a market with modest volumes is mostly noise, and reacting to it produces stop start spending that makes everything worse. What deserves a monthly look is whether the cost is drifting in one direction across several periods, and whether the split between direct and partner routes is changing without anyone deciding that it should.
A residence field captured at registration, a case record in the CRM that can hold several contacts from one family, a first contact timestamp that cannot be edited, and an export that lets a finance analyst join cases to arrivals independently. The commission amounts should sit against individual cases rather than as an average rate, because averages hide both the best and the worst arrangements you have.
Plan for a quarter. The first weeks go into the arrival count and the registration habit, the next weeks into reconstructing one quarter of cost by hand from the ledger, and the rest into agreeing allocation rules that finance will sign. Teams that try to shortcut the manual reconstruction usually miss spend sitting in other cost centres and have to redo the work later.
Avoid redefining it mid year, averaging partner commissions into a single rate, and using it to rank markets. Its value is almost entirely in the trend, so stability of definition beats precision. Also avoid presenting it without saying what sits inside it. A number that arrives with its allocation rule attached survives questioning; a number that arrives alone becomes the subject of the meeting.
